The history of pneumococcal conjugate vaccine development: dose selection
Authors:
- Carla Cam PeetersCPCarla Cam Peeters
- Germie Pjm van Den DobbelsteenGDGermie Pjm van Den Dobbelsteen
- 1 December 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 12 (12) , 1379-1394
Abstract
Pneumococcal conjugate vaccines (PCVs) differ in polysaccharide (PS) dose, carrier protein and conjugation method. PCV development proceeded initially upon principles successfully proven in Haemophilus influenzae type b (Hib) conjugate vaccine development. However, the need to successfully incorporate multiple serotypes while minimizing the total PS dose and total carrier protein load saw some early vaccine candidates fail. Dose-range studies of individual serotypes indicated that much lower PS doses were needed compared with Hib conjugate vaccines, although subsequent studies confirmed that lower Hib PS doses were possible. Furthermore, the immune response to individual serotype doses was carrier protein dependent. A 'one-size fits most' approach has characterized PS dose selection, but peculiarities of individual serotypes are increasingly apparent, raising the question whether re-formulation of PCVs to maximize individual serotype performance is needed.Keywords
This publication has 98 references indexed in Scilit:
- Prediction of Pneumococcal Conjugate Vaccine Effectiveness against Invasive Pneumococcal Disease Using Opsonophagocytic Activity and Antibody Concentrations Determined by Enzyme-Linked Immunosorbent Assay with 22F AdsorptionClinical and Vaccine Immunology, 2011
- Impact of the Conjugation Method on the Immunogenicity of Streptococcus pneumoniae Serotype 19F Polysaccharide in Conjugate VaccinesClinical and Vaccine Immunology, 2011
- The Capsular Serotype ofStreptococcus pneumoniaeIs More Important than the Genetic Background for Resistance to ComplementInfection and Immunity, 2010
- Serotype-Related Variation in Susceptibility to Complement Deposition and Opsonophagocytosis among Clinical Isolates of Streptococcus pneumoniaeInfection and Immunity, 2010
- Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and ToddlersClinical and Vaccine Immunology, 2010
- Evaluation of Pneumococcal Polysaccharide Immunoassays Using a 22F Adsorption Step with Serum Samples from Infants Vaccinated with Conjugate VaccinesClinical and Vaccine Immunology, 2010
- Animal Models ofStreptococcus pneumoniaeDiseaseClinical Microbiology Reviews, 2008
- Effects of Ageing and Gender on Naturally Acquired Antibodies to Pneumococcal Capsular Polysaccharides and Virulence-Associated ProteinsClinical and Vaccine Immunology, 2008
- Functional Antibodies Elicited by Two Heptavalent Pneumococcal Conjugate Vaccines in the Finnish Otitis Media Vaccine TrialInfection and Immunity, 2007
- Capsule Enhances Pneumococcal Colonization by Limiting Mucus-Mediated ClearanceInfection and Immunity, 2007